Tag Archives: Asma

Selective Provision of Asthma Self-Management Tools to Families


Published online April 1, 2008 PEDIATRICS Vol. 121 No. 4 April 2008, pp. e900-e905 (doi:10.1542/peds.2007-1559) This Article Full Text Full Text (PDF) P3Rs: Submit a response Alert me when this article is cited Alert me when P3Rs are posted Alert … Continue reading

Posted in Asma | Tagged , , , , | Leave a comment

Macrólidos para el asma crónica


Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG Éste es el resumen de una revisión Cochrane traducida. La Colaboración Cochrane prepara y actualiza estas revisiones sistemáticas. El texto completo de la revisión traducida se publica en La Biblioteca … Continue reading

Posted in Asma, Colaboracion Cochrane, Macrolidos | Tagged , , , | Leave a comment

En las reagudizaciones del asma, el aumento de las dosis previas de corticoides inhalados no produce beneficio


  Artículos relacionados en EvidPediatr PubMed sobre este tema Scholar sobre este tema Artículo en pdf Versión para imprimir Buscar: autor: claves: Búsqueda avanzada University of Michigan Department of Pediatrics Evidence-Based Pediatrics Web Site. Critically Appraised Topics (Temas Valorados Críticamente). … Continue reading

Posted in Asma, Evidencias en Pediatria, Medicamentos | Tagged , , , , , , | 1 Comment

Budesonide – Formoterol


Title Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Comments Erratum in: Eur Respir J. 2003 May;21(5):912. Authors Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H Source … Continue reading

Posted in Asma, Colaboracion Cochrane, Medicamentos, Medicina Basada en la Evidencia | Tagged , , , | 1 Comment

En las reagudizaciones del asma, el aumento de las dosis previas de corticoides inhalados no produce beneficio


  Artículos relacionados en EvidPediatr PubMed sobre este tema Scholar sobre este tema Artículo en pdf Versión para imprimir Buscar: autor: claves: Búsqueda avanzada University of Michigan Department of Pediatrics Evidence-Based Pediatrics Web Site. Critically Appraised Topics (Temas Valorados Críticamente). … Continue reading

Posted in Asma, pediatria, Salud Infantil | Tagged , , , , | Leave a comment

La lactancia materna no es protectora contra asma y alergia


Para evaluar si la lactancia materna exclusiva y prolongada disminuye el riesgo de asma y alergia en la niñez hasta la edad de 6.5 años, investigadores en Montreal y Belarus llevaron a cabo un estudio anidado randomizado en 31 hospitales … Continue reading

Posted in Lactancia materna | Tagged , , , , | Leave a comment

Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children


EBM Reviews – Cochrane Database of Systematic Reviews Ducharme, FM. Di Salvio, F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. [Systematic Review] Cochrane Airways Group Cochrane Database of Systematic … Continue reading

Posted in Asma, Colaboracion Cochrane | Tagged , , , , , , | Leave a comment

The Lancet: Articulos de interes


Safety of drug-eluting stents: demystifying network meta-analysis Given concerns about the safety of drug-eluting stents, Christoph Stettler and colleagues (Sept 15, p 937) provide the most extensive meta-analysis to date comparing sirolimus-eluting stents, paclitaxel-eluting stents, and bare-metal stents: 38 trials … Continue reading

Posted in Articulos de interés, The Lancet | Tagged , , , , , , , | Leave a comment

AP al dia: Resumenes comentados


¿Cuál es el valor diagnóstico de los datos clínicos sugestivos de artritis séptica? HTML PPT La restricción de la ingesta de sal previene las enfermedades cardiovasculares en personas con prehipertensión HTML PPT La angioplastia coronaria en pacientes con angina estable … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Sesgo de publicacion o sesgo de financiamiento? * Sign In to E-Mail or Save This * Print * Reprints * Share o Del.icio.us o Digg o Facebook o Newsvine o Permalink Article Tools Sponsored By By ERIC NAGOURNEY Published: November 13, 2007 Sesgo de publicacion o sesgo de financiamiento?


By ERIC NAGOURNEY Published: November 13, 2007 Inhalers are an effective treatment for asthma and other respiratory diseases, but they can have adverse side effects. The conclusions of studies on these effects apparently depend in part on who pays for … Continue reading

Posted in Industria Farmaceutica, sesgo | Tagged , , , , , , , | Leave a comment

Sesgo de publicacion o sesgo de financiamiento? * Sign In to E-Mail or Save This * Print * Reprints * Share o Del.icio.us o Digg o Facebook o Newsvine o Permalink Article Tools Sponsored By By ERIC NAGOURNEY Published: November 13, 2007 Sesgo de publicacion o sesgo de financiamiento?


By ERIC NAGOURNEY Published: November 13, 2007 Inhalers are an effective treatment for asthma and other respiratory diseases, but they can have adverse side effects. The conclusions of studies on these effects apparently depend in part on who pays for … Continue reading

Posted in Industria Farmaceutica, sesgo | Tagged , , , , , , | Leave a comment

Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial


The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading

Posted in Asma, Medicamentos, mortalidad, Salud Infantil | Tagged , , , , , | Leave a comment

Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial


The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading

Posted in Asma, Medicamentos, mortalidad, Salud Infantil | Tagged , , , , | Leave a comment

AP al dia: resúmenes comentados


El tratamiento de la obesidad importante mediante cirugía bariátrica se asocia a una menor mortalidad HTML PPT ¿Es eficaz el cribado de la fibrilación auricular en atención primaria? HTML PPT Relación entre el consumo habitual de Cannabis y el desarrollo … Continue reading

Posted in Articulos de interés | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

National Asthma Guidelines Updated


National Asthma Guidelines Updated BETHESDA, MD — September 5, 2007 — The National Asthma Education and Prevention Program (NAEPP) issued the first comprehensive update in a decade of clinical guidelines for the diagnosis and management of asthma. The guidelines emphasize … Continue reading

Posted in Asma, Guias Clinicas | Tagged , , , , , | Leave a comment

Tratamientos del asma Basados en la Evidencia


“No existe ningún problema, por complicado que sea, que cuando se analiza adecuadamente, no se complique más aún”. A. Koestler Tratamientos del asma Basados en la Evidencia Dr. D. Pere Casan Clará. Departamento de Pneumología. Hospital de la Santa Creu … Continue reading

Posted in Asma, Medicina Basada en la Evidencia | Tagged , , , , | Leave a comment